Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

8 trials match this view; 2 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 179 across 8 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

202322
202422
202522
202622

Current indexed registry status

Completed33
Recruiting33
Active, not recruiting11
Not yet recruiting11

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

8 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment

NCT06041152

Amnestic Mild Cognitive Impairment
Centre for Addiction and Mental Health

PHASE2

Completed

Registry updated 2026-10-05

10

ACTUAL

2023-11-27
2026-02-19
2026-02-19
Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial

NCT06299319

Obsessive-Compulsive Disorder
Centre for Addiction and Mental Health

PHASE1

Completed

Registry updated 2026-09-24

10

ACTUAL

2024-09-01
2026-09-04
2026-09-04
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

NCT07211438

Treatment-Resistant Depression
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-08-21

40

ESTIMATED

2026-07-03
2028-07
2029-01
Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism

NCT06731621

Treatment Resistant Depression · Autism Spectrum Disorder
Centre for Addiction and Mental Health

PHASE1

Active, not recruiting

Registry updated 2026-08-06

20

ESTIMATED

2024-11-01
2026-12
2026-12
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

NCT06512220

Treatment Resistant Depression
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-07-30

12

ESTIMATED

2025-04-21
2027-04
2027-09
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial

NCT06518720

Treatment Resistant Depression · Chronic Pain
Centre for Addiction and Mental Health

PHASE2

Recruiting

Registry updated 2026-07-30

16

ESTIMATED

2025-04-01
2027-03
2027-12
Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial

NCT05710237

Treatment-resistant Depression
Centre for Addiction and Mental Health

PHASE2

Completed

Registry updated 2026-05-07

41

ACTUAL

2023-07-01
2026-04-14
2026-04-14
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial

NCT07405606

Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD)
Centre for Addiction and Mental Health

PHASE2

Not yet recruiting

Registry updated 2026-02-12

30

ESTIMATED

2026-03
2028-03
2028-06

Reported research facilities

Centre for Addiction and Mental HealthToronto, Ontario, Canada
Toronto Western Hospital (University Health Network)Toronto, Ontario, Canada

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.